Botulinum toxin treatments of depression
AssigneeAllergan, Inc.
InventorAndrew M. Blumenfeld
Life of this patent
Estimating the term…
Abstract
Methods for preventing or treating depression including a depression mediated by the thalamus. Depression, including a thalamically mediated depression, can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating the depression.
Claims7
A method for treating depression comprising directly administering a botulinum toxin to a trigeminal nerve of a human patient with depression, thereby decreasing the depression.
A method for treating depression comprising locally administering a therapeutically effective amount of a botulinum toxin subdermally, non-intramuscularly to a trigeminal sensory nerve of a human patient with depression, thereby treating the depression by reducing the occurrence of a symptom of the depression.
Dependencies are inferred from the claim text.